Publications by authors named "Elizabeth A Krueger"
Article Synopsis
- Amplification acts as a resistance mechanism in ALK+ lung cancer, and this study focuses on treatment outcomes for patients with this specific molecular profile.
- A cohort of 12 patients receiving combined ALK and MET-targeting regimens showed partial responses in 42% of cases, highlighting some effectiveness but also significant side effects, such as peripheral edema.
- The findings suggest that while there is moderate antitumor activity from combined therapy, further prospective studies are needed to better understand benefits and target suitable patients.
Article Synopsis
- Lorlatinib, a cancer treatment, is associated with various neurocognitive adverse events (NAEs), affecting a significant portion of patients (60% at MGH and 49% in another study).
- Factors like brain metastases, psychiatric conditions, and certain medications are linked to the development of cognitive and mood-related effects.
- Dose reductions were necessary for many patients experiencing NAEs, indicating a potential strategy to mitigate these cognitive impacts.
Introduction: The central nervous system (CNS) is a common site of progression among patients with -rearranged lung cancer receiving crizotinib. We conducted a phase 2 study to evaluate the intracranial efficacy of lorlatinib in patients with -rearranged lung cancer who developed CNS-only progression on crizotinib.
Methods: Patients with metastatic -rearranged lung cancer with CNS-only progression on crizotinib received lorlatinib 100 mg daily.